Coronary heart disease and hormone replacement therapy - From primary and secondary prevention to the window of opportunity

Neuroendocrinology Letters

Volumn 33, Issue SUPPL. 2, 2012, Pages 17-21

  Fait, Tomas ^a   Vrablik, Michal ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Cardiovascular system; Coronary heart disease; Hormone replacement therapy; Window of opportunity

Indexed keywords

CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE;

ADULT; AGED; CONFERENCE PAPER; DISEASE COURSE; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; PRIMARY PREVENTION; SECONDARY PREVENTION;

EID: 84871069006     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. Allison MA, Manson JE, Langer RD (2008). Oophorectomy, hormone therapy, and subclinical coronary artery disease in women with hysterectomy: the Women's Health Initiative coronary artery calcium study. Menopause. 15: 639-647.
2. Beral V, Banks E, Reeves G (2002). Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet. 360: 942-944. (Pubitemid 35283842)
3. Colditz GA (1987). Menopause and the risk of coronary heart disease in women. New E J Med 316: 1105-1110.
4. Collins P, Rosano G, Casey C, Daly C, Gambacciani M, Hadji P et al (2007). Management of cardiovascular risk in peri-menopausal woman. Eur Heart J. 28: 2028-2040.
5. Furberg CD (2002). Subgroup interactions in the heart and estrogen progestin replacement study. Circulation. 105: 917-922.
6. Fait T, Vrablik M, Cibula D, Masata J, Hill M, Trnkova B (2006a). Oral but not transdermal estrogen replacement therapy reduced level of tissue factor pathway inhibitor: Cross-over Designed Study. Neuro Endocrinol Lett. 27: 557-561.
7. Fait T, Vrablik M, Koštířová M, Trnková B (2006b). Vliv různých aplikačních forem estrogenní substituční terapie na hladiny C-reaktivního proteinu [(Influence of different application ways of estrogene replacement therapy on CRP levels) (In Czech with English abstract]. Čas lék česk. 145: 571-574. (Pubitemid 44265225)
8. Fait T, Vrablík M, Zizka Z, Kostirova M (2008). Changes in Haemostatic Variables Induced by Estrogen Replacement Therapy: Comparison of Transdermal and Oral Methods of Administration in Cross-over Designed Study. Gynaecol Obstet Invest. 65: 47-51.
9. Grodstein F, Stampfer MJ (1996). Selection bias and studies of HRT, European consensus development conference, Montreux, p. 151-6.
10. Grodstein F (1996). Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. New E J Med 335: 453-461.
11. Grodstein F, Manson JE, Stampfer MJ (2006) Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health. 15: 35-44. (Pubitemid 43192860)
12. Gruchow HW, Anderson AJ, Barboriah JJ, Sulocinski KA (1988). Postmenopausal use of estrogen and occlusion of coronary arteries. Am Heart J. 115: 954-963.
13. Haarbo J (1991). Postmenopausal HRT prevents central distribution of body fat after menopause. Metabolism. 40: 1323-6.
14. Henderson BE, Paganini-Hill A, Ross RK (1991). Decreased mortality in user of ERT. Arch Intern Med. 151: 269-277.
15. Hodis HN, Collins P, Mack WJ, Schierbeck LL (2012). The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future perspective. Climacteric 15: 217-228.
16. Hodis HN, St John JA, Xiang M et al. (2008). Inflammatory markers and progression of subclinical atherosclerosis in healthy postmenopausal women (from the Estrogen in the Prevention of Atherosclerosis Trial). Am J Cardiol. 15: 1131-1133.
17. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B et al (1998). Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280: 605-613. (Pubitemid 28502636)
18. Mendelsohn ME, Karas RH (2001). The Time Has Come to stop letting the HERS tale wag the dogma. Circulation 104: 2256-2259. (Pubitemid 33049502)
19. Mueck AO (2012). Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone. Climacteric. 15 (Suppl. 1): 11-17.
20. Newton KM (1997). ERT and prognosis after first myocardial infarction. Am J Epid. 145: 269-277.
21. Pines A, Fisman EZ, Ayalon D, Dory Y, Averbuch M, Levo Y (1992). Long-term effects of hormone replacement therapy on Doppler-derived parameters of aortic flow in postmenopausal women. Chest. 102: 1496-1498.
22. Rosano G, Vitale C, Spoletini I, Fini M (2012). Cardiovascular health in the menopausal woman: impact of the timing of hormone replacement therapy. Climacteric. 15: 299-305.
23. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 288: 321-333. (Pubitemid 34761611)
24. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM et al (2007). Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 297: 1465-1477. (Pubitemid 46556472)
25. Salpeter SR, Walsh JM, Greyber E, Ormiston TM, Salpeter EE (2004). Mortality associated with HRT in younger and older women. J Gen Intern Med. 19: 791-804.
26. Shlipak MG, Angeja BG, Go AS, Frederick PD, Canto JG, Grady D (2001). Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women. Circulation. 104: 2300-2304. (Pubitemid 33049512)
27. The Writing Group for the PEPI Trial (1995). Effect of estrogen or estrogen/progestin regimens on heart disease factors in postmenopausal women. JAMA. 273: 199-208.
28. Van de Mooren MJ (1995). HRT may reduce high serum homocystein in postmenopausal women. Eur J Clin Invest. 24: 733-736.
29. Walsh BW (1991). Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. New E J Med. 325: 1196-1204.